BioCentury | Dec 2, 2020

Data Byte: IPO queue picks up post-election

While IPO activity came to a brief standstill early last month in anticipation of post-election market volatility, at least eight biotechs have since lined up for a NASDAQ listing.  And the postmarket performance of Olema...
BioCentury | Nov 26, 2020

Pre-profit biotechs on Hong Kong exchange, STAR board could see investment influx via Stock Connect expansion

Pre-profit biotechs listed on the Hong Kong stock exchange or Shanghai’s STAR board could soon see an influx of investment as the Chinese government expands the Stock Connect channel linking financial...
BioCentury | Oct 31, 2020
Product Development

Oct. 30 Quick Takes: Aducanumab heads to EMA; plus Boehringer, Arcus-AZ, Tricida

EMA accepts aducanumab MAA for reviewBiogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) said the EMA accepted for review an MAA for Alzheimer’s disease candidate aducanumab. The anti-amyloid mAb will undergo standard review, putting a...
BioCentury | Oct 30, 2020
Distillery Therapeutics

Targeting water channel AQP1 for hypertrophic cardiomyopathy

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiomyopathy Inhibiting AQP1, a water channel expressed in cardiac and vascular tissues, could treat hypertrophic cardiomyopathy. Among 26 patients with aortic stenosis, high AQP1 mRNA expression in cardiac biopsies was associated with...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Targeting the NMDA receptor-TRPM4 complex for neurodegeneration

DISEASE CATEGORY: Neurology INDICATION: Stroke; neurology Disruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor involvement. In mouse hippocampal neurons deprived of oxygen and glucose or treated...
BioCentury | Oct 17, 2020

Praxis sees strongest first-day among trio of IPOs as NASDAQ nears $16B raised in fresh paper

Among a trio of clinical biotechs pricing IPOs ahead of Friday’s NASDAQ session, demand was highest for Praxis as the company posted a 46% gain, while the reception was more muted for Aligos and Tarsus...
BioCentury | Oct 15, 2020

Larger stakes, more newcos as Canaan moves to bump up biopharma investments with new $800M fund

With 40% of its new $800 million fund dedicated to healthcare, Canaan plans to ramp up biopharma investments and de novo company formation as it seeks larger ownership stakes. “Given the increased capital...
BioCentury | Oct 8, 2020
Product Development

Mapping opportunities for China’s early cancer detection boom

As investor enthusiasm for blood-based cancer screening soars in the wake of Grail’s $8 billion acquisition,  much of the activity is taking place in China, where a short list of dominant cancers, out-of-pocket spending habits...
BioCentury | Oct 8, 2020

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

Genor’s $371 million IPO on the Hong Kong stock exchange’s prerevenue chapter Wednesday caps a busy 12 months for the Shanghai cancer company during which it has rebooted its C-suite, added dry powder via a...
BioCentury | Oct 7, 2020

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

Roche’s deal to acquire a clinical cystic fibrosis program from U.K.-based Enterprise delivers a return to the biotech’s shareholders while allowing the venture-backed company to continue development of another pipeline project. Roche (SIX:ROG; OTCQX:RHHBY) is...
Items per page:
1 - 10 of 3269